Halozyme Therapeutics, Inc. – LSE:0J2O.L
Halozyme Therapeutics stock price today
Halozyme Therapeutics stock price monthly change
Halozyme Therapeutics stock price quarterly change
Halozyme Therapeutics stock price yearly change
Halozyme Therapeutics key metrics
Market Cap | 5.96B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 2.46 |
Revenue | 862.98M |
EBITDA | 461.18M |
Income | 318.80M |
Revenue Q/Q | 20.80% |
Revenue Y/Y | 22.41% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 53.44% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHalozyme Therapeutics stock price history
Halozyme Therapeutics stock forecast
Halozyme Therapeutics financial statements
| Jun 2023 | 221.03M | 74.75M | 33.82% |
|---|---|---|---|
| Sep 2023 | 216.03M | 81.83M | 37.88% |
| Dec 2023 | 230.03M | 85.38M | 37.12% |
| Mar 2024 | 195.87M | 76.82M | 39.22% |
| Dec 2023 | 230.03M | 85.38M | 37.12% |
|---|---|---|---|
| Mar 2024 | 195.87M | 76.82M | 39.22% |
| Sep 2025 | 295.45M | 152.08M | 51.48% |
| Dec 2025 | 302.47M | 160.46M | 53.05% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1810440000 | 1.65B | 91.66% |
|---|---|---|---|
| Sep 2023 | 1892662000 | 1.64B | 86.83% |
| Dec 2023 | 1733270000 | 1.64B | 95.16% |
| Mar 2024 | 1841527000 | 1.66B | 90.34% |
| Jun 2023 | 66.84M | 54.99M | 2.44M |
|---|---|---|---|
| Sep 2023 | 132.41M | -83.45M | 4.10M |
| Dec 2023 | 102.35M | -8.29M | -249.92M |
| Mar 2024 | 129.42M | -82.68M | -489K |
Halozyme Therapeutics alternative data
| Aug 2023 | 393 |
|---|---|
| Sep 2023 | 393 |
| Oct 2023 | 393 |
| Nov 2023 | 393 |
| Dec 2023 | 393 |
| Jan 2024 | 393 |
| Feb 2024 | 393 |
| Mar 2024 | 373 |
| Apr 2024 | 373 |
| May 2024 | 373 |
| Jun 2024 | 373 |
| Jul 2024 | 373 |
Halozyme Therapeutics other data
| Insider | Compensation |
|---|---|
| Dr. Helen I. Torley (1963) Pres, Chief Executive Officer & Director | $1,490,000 |
| Mr. William J. Fallon Senior Vice President &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances | |
Mr. Ed Gemo Vice President, Chief Information & Security Officer | |
Ms. Amy Marinne Fox Vice President of HR | |
Mr. Albert S. Kildani Vice President of Investor Relations & Corporation Communications | |
Mr. Todd Butler Chief of Staff to the Chief Executive Officer, Vice President & Head of Project Management | |
| Ms. Elaine D. Sun Senior Vice President & Chief Financial Officer | |
| Dr. Michael J. LaBarre Senior Vice President & Chief Technical Officer | |
Dr. Steve Knowles Chief Medical Officer | |
| Mr. Masaru Matsuda Esq. Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec. |
-
What's the price of Halozyme Therapeutics stock today?
One share of Halozyme Therapeutics stock can currently be purchased for approximately $39.94.
-
When is Halozyme Therapeutics's next earnings date?
Unfortunately, Halozyme Therapeutics's (0J2O.L) next earnings date is currently unknown.
-
Does Halozyme Therapeutics pay dividends?
No, Halozyme Therapeutics does not pay dividends.
-
How much money does Halozyme Therapeutics make?
Halozyme Therapeutics has a market capitalization of 5.96B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 25.62% to 829.25M US dollars.
-
What is Halozyme Therapeutics's stock symbol?
Halozyme Therapeutics, Inc. is traded on the LSE under the ticker symbol "0J2O.L".
-
What is Halozyme Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Halozyme Therapeutics?
Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Halozyme Therapeutics's key executives?
Halozyme Therapeutics's management team includes the following people:
- Dr. Helen I. Torley Pres, Chief Executive Officer & Director(age: 62, pay: $1,490,000)
- Mr. William J. Fallon Senior Vice President &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances
- Mr. Ed Gemo Vice President, Chief Information & Security Officer
- Ms. Amy Marinne Fox Vice President of HR
- Mr. Albert S. Kildani Vice President of Investor Relations & Corporation Communications
- Mr. Todd Butler Chief of Staff to the Chief Executive Officer, Vice President & Head of Project Management
- Ms. Elaine D. Sun Senior Vice President & Chief Financial Officer
- Dr. Michael J. LaBarre Senior Vice President & Chief Technical Officer
- Dr. Steve Knowles Chief Medical Officer
- Mr. Masaru Matsuda Esq. Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec.
-
How many employees does Halozyme Therapeutics have?
As Jul 2024, Halozyme Therapeutics employs 373 workers.
-
When Halozyme Therapeutics went public?
Halozyme Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Halozyme Therapeutics's official website?
The official website for Halozyme Therapeutics is halozyme.com.
-
Where are Halozyme Therapeutics's headquarters?
Halozyme Therapeutics is headquartered at 11388 Sorrento Valley Road, San Diego, CA.
-
How can i contact Halozyme Therapeutics?
Halozyme Therapeutics's mailing address is 11388 Sorrento Valley Road, San Diego, CA and company can be reached via phone at 858 794 8889.
Halozyme Therapeutics company profile:
Halozyme Therapeutics, Inc.
halozyme.comLSE
373
Medical - Pharmaceuticals
Healthcare
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
San Diego, CA 92121
:
ISIN: US40637H1095
:
